Literature DB >> 3142665

A comparison of the pharmacokinetics of 14C-labelled APD and 99mTc-labelled APD in the mouse.

P T Daley-Yates1, R Bennett.   

Abstract

The disposition of 14C-labelled and 99mTc-labelled APD has been investigated in the Balb/c mouse following a single ip injection containing APD (total dose 5 mg/kg) labelled partly with carbon-14 and partly with technetium-99m. The plasma clearance of carbon-14 was twice that for technetium-99m and the accumulation of carbon-14 in bone was twice as great as that of technetium-99m. All other tissues assayed (liver, lung, kidney and muscle) contained higher concentrations of technetium-99m than carbon-14. There was a particularly marked accumulation of technetium-99m in the liver. We conclude that pharmacokinetic studies of diphosphonates cannot be conducted reliably with 99mTc-labelled compounds.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142665     DOI: 10.1007/bf02555158

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  3 in total

1.  Absorption of oral diphosphonate in normal subjects.

Authors:  I Fogelman; L Smith; R Mazess; M A Wilson; J A Bevan
Journal:  Clin Endocrinol (Oxf)       Date:  1986-01       Impact factor: 3.478

2.  Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique.

Authors:  R R Recker; P D Saville
Journal:  Toxicol Appl Pharmacol       Date:  1973-04       Impact factor: 4.219

Review 3.  Diphosphonates: history and mechanisms of action.

Authors:  H Fleisch
Journal:  Metab Bone Dis Relat Res       Date:  1981
  3 in total
  3 in total

1.  The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.

Authors:  P T Daley-Yates; D J Dodwell; M Pongchaidecha; R E Coleman; A Howell
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

Review 2.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

3.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.